×
About 18,907 results

ALLMedicine™ Non-Hodgkin Lymphoma Center

Research & Reviews  8,763 results

18F-FDG positron emission tomography scanning in systemic sclerosis-associated intersti...
https://doi.org/10.1186/s13075-021-02460-8 10.1007/s12016-010-8198-y 10.1007/s12016-009-8194-2 10.1136/ard.2006.066068 10.1186/s13075-019-1867-1 10.1164/rccm.2106012 10.1002/art.39166 10.1093/rheumatology/kev016 10.2147/OARRR.S226695 10.1002/art.22204 10.1056/NEJMoa055120 10.1002/art.40114 10.1136/annrheumdis-2016-209909 10.5301/jsrd.5000205 10.1186/s13075-015-0872-2 10.1378/chest.13-2626 10.1371/journal.pone.0181692 10.1097/BOR.0000000000000656 10.1136/thoraxjnl-2018-211779 10.1056/NEJMoa1903076 10.2967/jnumed.116.174946 10.1016/j.ejrad.2016.10.001 10.1007/s00259-013-2514-8 10.1007/s12350-016-0649-2 10.4103/0972-3919.178335 10.4103/0972-3919.164018 10.1164/rccm.201308-1483ST 10.1088/0031-9155/60/18/7387 10.2967/jnumed.116.184796 10.4329/wjr.v6.i10.779 10.1002/art.38098 10.1164/rccm.200706-877OC 10.1093/rheumatology/ken271 10.2967/jnumed.114.147421 10.1164/rccm.201504-0780OC 10.1164/rccm.201508-1699ED 10.1016/j.ejrad.2016.09.014 10.1186/s12931-017-0556-3 10.2967/jnumed.115.163360 10.1097/MNM.0000000000000083 10.1007/s00259-011-1986-7 10.1007/s00259-009-1069-1 10.1136/annrheumdis-2018-21337652 10.1016/S1095-0397(99)00016-3
Arthritis Research & Therapy; Ledoult E, Morelle M et. al.

Mar 6th, 2021 - Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool i...

Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.
https://doi.org/10.1016/S2352-3026(21)00058-2
The Lancet. Haematology; Thanarajasingam G, Smedby KE et. al.

Mar 5th, 2021 - Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.|2021|Thanarajasingam G,Smedby KE,LaCasce A,|

American Journal of Hematology: Annual Clinical Updates in Hematologic Malignancies.
https://doi.org/10.1002/ajh.26151
American Journal of Hematology; Susanibar-Adaniya S, Barta SK

Mar 4th, 2021 - Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R-CHOP remains the mainstay of therap...

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis...
https://doi.org/10.1182/bloodadvances.2020003666
Blood Advances; Khurana A, Novo M et. al.

Mar 4th, 2021 - Neurolymphomatosis (NL) is a rare manifestation of lymphoma, with limited evidence for optimal management. The largest patient series, 50 cases of lymphoma and leukemia, was published in 2010 with limited rituximab exposure. This study aims to eva...

see more →

Guidelines  59 results

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
https://www.targetedonc.com/view/car-t-cell-therapy-with-axi-cel-holds-promise-in-r-r-indolent-nhl

May 29th, 2020 - Patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor (CAR) T-cell therapy of axicabtagene ciloleucel (axi-cel; Yescarta) had high rates of complete response (CR) and demonstrated th...

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl

May 29th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, ...

see more →

Drugs  75 results see all →

Clinicaltrials.gov  9,381 results

18F-FDG positron emission tomography scanning in systemic sclerosis-associated intersti...
https://doi.org/10.1186/s13075-021-02460-8 10.1007/s12016-010-8198-y 10.1007/s12016-009-8194-2 10.1136/ard.2006.066068 10.1186/s13075-019-1867-1 10.1164/rccm.2106012 10.1002/art.39166 10.1093/rheumatology/kev016 10.2147/OARRR.S226695 10.1002/art.22204 10.1056/NEJMoa055120 10.1002/art.40114 10.1136/annrheumdis-2016-209909 10.5301/jsrd.5000205 10.1186/s13075-015-0872-2 10.1378/chest.13-2626 10.1371/journal.pone.0181692 10.1097/BOR.0000000000000656 10.1136/thoraxjnl-2018-211779 10.1056/NEJMoa1903076 10.2967/jnumed.116.174946 10.1016/j.ejrad.2016.10.001 10.1007/s00259-013-2514-8 10.1007/s12350-016-0649-2 10.4103/0972-3919.178335 10.4103/0972-3919.164018 10.1164/rccm.201308-1483ST 10.1088/0031-9155/60/18/7387 10.2967/jnumed.116.184796 10.4329/wjr.v6.i10.779 10.1002/art.38098 10.1164/rccm.200706-877OC 10.1093/rheumatology/ken271 10.2967/jnumed.114.147421 10.1164/rccm.201504-0780OC 10.1164/rccm.201508-1699ED 10.1016/j.ejrad.2016.09.014 10.1186/s12931-017-0556-3 10.2967/jnumed.115.163360 10.1097/MNM.0000000000000083 10.1007/s00259-011-1986-7 10.1007/s00259-009-1069-1 10.1136/annrheumdis-2018-21337652 10.1016/S1095-0397(99)00016-3
Arthritis Research & Therapy; Ledoult E, Morelle M et. al.

Mar 6th, 2021 - Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool i...

Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.
https://doi.org/10.1016/S2352-3026(21)00058-2
The Lancet. Haematology; Thanarajasingam G, Smedby KE et. al.

Mar 5th, 2021 - Late toxicities in non-Hodgkin lymphoma: extended follow-up matters.|2021|Thanarajasingam G,Smedby KE,LaCasce A,|

American Journal of Hematology: Annual Clinical Updates in Hematologic Malignancies.
https://doi.org/10.1002/ajh.26151
American Journal of Hematology; Susanibar-Adaniya S, Barta SK

Mar 4th, 2021 - Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R-CHOP remains the mainstay of therap...

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis...
https://doi.org/10.1182/bloodadvances.2020003666
Blood Advances; Khurana A, Novo M et. al.

Mar 4th, 2021 - Neurolymphomatosis (NL) is a rare manifestation of lymphoma, with limited evidence for optimal management. The largest patient series, 50 cases of lymphoma and leukemia, was published in 2010 with limited rituximab exposure. This study aims to eva...

see more →

News  627 results

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

Patients With Lung and Blood Cancers Most Vulnerable to COVID-19
https://www.medscape.com/viewarticle/942430

Dec 9th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are at significantly increased risk for COVID-19 and worse outcomes, a new review confirms. It also found that patients with ...

CAR T for All R/R DLBCL Patients: The Jury Is Still Out
https://www.medscape.com/viewarticle/939947

Oct 27th, 2020 - Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD. CAR T-cell therapy has demonstrated activity in relapsed/re...

see more →

Patient Education  2 results see all →